Actively Recruiting

All Genders
NCT06539169

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Led by xCures · Updated on 2024-11-14

1000

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in the study by electronic consent (eConsent) and sign a medical records release to permit data collection. Medical records are accessed from institutions directly via eFax or paper fax, online from patient electronic medical record (EMR) portals, direct from DNA/RNA sequencing and molecular profiling vendors, and via electronic health information exchanges. Patients and their treating physicians may also optionally provide medical records. Medical records are received in or converted to electronic/digitized formats (CCDA, FHIR, PDF), sorted by medical record type (clinic visit, in-patient hospital, out-patient clinic, infusion and out-patient pharmacies, etc.) and made machine-readable to support data annotation, full text searches, and natural language processing (NLP) algorithms to further facilitate feature identification.

CONDITIONS

Official Title

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Any person with a known or suspected rare disease affecting fewer than 200,000 individuals nationwide, including but not limited to Alpha- or Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeldt-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-onset Alzheimer's Disease, Ehlers-Danlos Syndrome, Huntington's Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, and Transthyretin Amyloid Polyneuropathy
  • Patients or their legally authorized representative must be willing and able to provide informed consent (and assent, if applicable)
  • Deceased persons may participate if consent is provided by their legally authorized representative according to applicable laws
Not Eligible

You will not qualify if you...

  • Patient or legally authorized representative is unable to provide informed consent
  • Patient resides outside the United States and cannot provide access to medical records

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

xCures

Los Altos, California, United States, 94022

Actively Recruiting

Loading map...

Research Team

M

Mark Shapiro, MS

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases | DecenTrialz